Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Xerion Pharmaceuticals Licenses Antibody Library from Cambridge Antibody Technology

NEW YORK, June 5 - Xerion Pharmaceuticals has signed a license to use Cambridge Antibody Technology's library of human phage antibodies in its protein target validation and internal drug discovery efforts, the companies said Tuesday. 

Xerion, based in Martinsried, Germany, will incorporate CAT's phage display technology into its platform for validating protein drug targets because it will give the company easy access to billions of possible antibodies, said Alexander Jaksch, the business development and marketing manager at Xerion. The company will pay CAT an undisclosed fee for the multi-year license.

The company's technology for validating protein targets involves a technique called chromophore-assisted laser inactivation (CALI), initially developed at Harvard University School of Medicine. To study a protein's function, Xerion first generates an antibody that binds to it, and then attaches a chromophore to the antibody. When the antibody-protein complex is irradiated with a laser, the chromophore alters the protein's active site, Jaksch explained, inhibiting its function. The technique is more powerful than just using an antibody to block a protein, said Jaksch, explaining that many antibodies are non-specific, and the CALI technique allows Xerion scientists to control precisely when to disrupt the active site.   

In March, Xerion raised $11.1 million euros ($9.4 million) in a second round private placement, and hired Markus Ewert as CEO from Axxima Pharmaceuticals, another Martinsried-based pharmacueutical company. The company has collaborations with TILL Photonics to develop additional CALI-based techniques, as well as with several academic partners, Jaksch said. Last year, the company concluded a pilot project with Aventis. The two companies are currently discussing additional work together, according to Jaksch.

CAT, in Cambridge, UK, has licensed its antibody library to a number of pharmaceutical and biotechnology companies, including Genentech, Pfizer, and Immunex.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.